- Home
- Publications
- Publication Search
- Publication Details
Title
Immunological off-target effects of imatinib
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 13, Issue 7, Pages 431-446
Publisher
Springer Nature
Online
2016-03-31
DOI
10.1038/nrclinonc.2016.41
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century
- (2015) A. J. Barrett et al. BLOOD
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
- (2015) S. Arai et al. CLINICAL CANCER RESEARCH
- Novel monogenic diseases causing human autoimmunity
- (2015) Isabelle Melki et al. CURRENT OPINION IN IMMUNOLOGY
- B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity
- (2015) M-R Wu et al. GENE THERAPY
- GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer
- (2015) Angela Cioffi et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
- (2015) Ming-Ru Wu et al. JOURNAL OF IMMUNOLOGY
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
- (2015) Jean-Yves Blay et al. LANCET ONCOLOGY
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
- (2015) L. Christiansson et al. MOLECULAR CANCER THERAPEUTICS
- Refining the treatment of NSCLC according to histological and molecular subtypes
- (2015) Anish Thomas et al. Nature Reviews Clinical Oncology
- Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
- (2015) Michaela Semeraro et al. Science Translational Medicine
- Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity
- (2015) Ruth J. Napier et al. PLoS Pathogens
- Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease
- (2014) J. M. Munneke et al. BLOOD
- Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor
- (2014) T. S. Kim et al. CLINICAL CANCER RESEARCH
- Identification of minor histocompatibility antigens based on the 1000 Genomes Project
- (2014) R. Oostvogels et al. HAEMATOLOGICA
- Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib
- (2014) Giovanni Carulli et al. HEMATOLOGICAL ONCOLOGY
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias
- (2014) Joseph Y. Shin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
- (2014) N. Larmonier et al. JOURNAL OF IMMUNOLOGY
- Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions
- (2014) E. Ullrich et al. JOURNAL OF IMMUNOLOGY
- Kit Regulates Maintenance of Quiescent Hematopoietic Stem Cells
- (2014) L. A. Thoren et al. JOURNAL OF IMMUNOLOGY
- Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib
- (2014) L. Legros et al. LEUKEMIA RESEARCH
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
- (2014) Hiroyuki Sako et al. PLoS One
- Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
- (2014) Cesarina Giallongo et al. PLoS One
- Nilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo
- (2014) Jiang Wei et al. PLoS One
- Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants
- (2014) C. Maisonneuve et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Minor histocompatibility antigens: past, present, and future
- (2014) Eric Spierings TISSUE ANTIGENS
- A dual role for autophagy in a murine model of lung cancer
- (2014) Shuan Rao et al. Nature Communications
- Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
- (2014) Anna Kreutzman et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation
- (2013) Eric Spierings et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
- (2013) A. Olivieri et al. BLOOD
- Defects in DBA: more than meets the eye
- (2013) L. Da Costa BLOOD
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity
- (2013) K. S. Reiners et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Long-term molecular remission with persistence ofBCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL
- (2013) Giovanni Riva et al. BRITISH JOURNAL OF HAEMATOLOGY
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- BAG-6, a jack of all trades in health and disease
- (2013) Janina Binici et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dendritic cell c-kit signaling and adaptive immunity
- (2013) Timothy B. Oriss et al. Current Opinion in Allergy and Clinical Immunology
- Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON)
- (2013) Noortje Thielen et al. EUROPEAN JOURNAL OF CANCER
- A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction
- (2013) Y. Shinohara et al. HAEMATOLOGICA
- Autophagy and Cellular Immune Responses
- (2013) Yuting Ma et al. IMMUNITY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- A Soluble Fragment of the Tumor Antigen BCL2-associated Athanogene 6 (BAG-6) Is Essential and Sufficient for Inhibition of NKp30 Receptor-dependent Cytotoxicity of Natural Killer Cells
- (2013) Janina Binici et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- KIT oncogene inhibition drives intratumoral macrophage M2 polarization
- (2013) Michael J. Cavnar et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
- (2013) Lisa Christiansson et al. PLoS One
- The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor
- (2013) Marka R. Crittenden et al. PLoS One
- Phase I clinical trial combining imatinib mesylate and IL-2
- (2013) Nathalie Chaput et al. OncoImmunology
- VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
- (2013) Magali Terme et al. OncoImmunology
- Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients
- (2013) Patricia Pautier et al. OncoImmunology
- Trabectedin
- (2013) Paola Allavena et al. OncoImmunology
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation
- (2012) F. Guimont-Desrochers et al. BLOOD
- IKDCs or B220+ NK cells are pre-mNK cells
- (2012) L. Zitvogel et al. BLOOD
- Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases
- (2012) Amit K. Garg et al. CANCER
- New insights into antigen specific immunotherapy for chronic myeloid leukemia
- (2012) Yangqiu Li et al. Cancer Cell International
- Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
- (2012) P. Sabbatini et al. CLINICAL CANCER RESEARCH
- Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral Immunity
- (2012) Michael C. Abt et al. IMMUNITY
- Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy
- (2012) Fabio Stagno et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo
- (2012) T. Zhang et al. JOURNAL OF IMMUNOLOGY
- Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
- (2012) M Talpaz et al. LEUKEMIA
- Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
- (2012) Ho-Young Yhim et al. LEUKEMIA RESEARCH
- The Abl and Arg Kinases Mediate Distinct Modes of Phagocytosis and Are Required for Maximal Leishmania Infection
- (2012) D. M. Wetzel et al. MOLECULAR AND CELLULAR BIOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase
- (2012) M. Garcia et al. Science Translational Medicine
- High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
- (2011) C. Quintarelli et al. BLOOD
- BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription
- (2011) Z. Sheng et al. BLOOD
- Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
- (2011) G. V. Helgason et al. BLOOD
- Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
- (2011) Kazuma Ohyashiki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Exploiting antitumor immunity to overcome relapse and improve remission duration
- (2011) Lei L. Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Evolving War on Cancer
- (2011) Daniel A. Haber et al. CELL
- Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
- (2011) N. Takahashi et al. HAEMATOLOGICA
- Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid–immunoglobulin complexes in humans
- (2011) Yun Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia
- (2011) Silvia Catellani et al. PLoS One
- Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In Vivo
- (2011) Mika Kijima et al. PLoS One
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion
- (2010) W. Zhang et al. CLINICAL CANCER RESEARCH
- Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
- (2010) Peter Rohon et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors
- (2010) Daniel Perez et al. INTERNATIONAL JOURNAL OF CANCER
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Abl Family Tyrosine Kinases Regulate Sialylated Ganglioside Receptors for Polyomavirus
- (2010) A. I. Swimm et al. JOURNAL OF VIROLOGY
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Lck is a key target of imatinib and dasatinib in T-cell activation
- (2010) K C Lee et al. LEUKEMIA
- Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib
- (2010) Giovanni Carulli et al. LEUKEMIA RESEARCH
- Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia
- (2010) Tim Luetkens et al. LEUKEMIA RESEARCH
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
- (2010) D D De Carvalho et al. ONCOGENE
- Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)
- (2010) A. Gupta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment
- (2009) G. Riva et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Migratory and Antigen Presentation Functions of IFN-Producing Killer Dendritic Cells
- (2009) N. Himoudi et al. CANCER RESEARCH
- The Dendritic Cell-like Functions of IFN-Producing Killer Dendritic Cells Reside in the CD11b+ Subset and Are Licensed by Tumor Cells
- (2009) M. Terme et al. CANCER RESEARCH
- Natural Killer Cell IFN- Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
- (2009) C. Menard et al. CANCER RESEARCH
- Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
- (2009) A. W. Gramza et al. CLINICAL CANCER RESEARCH
- Abl tyrosine kinases in T-cell signaling
- (2009) Jing Jin Gu et al. IMMUNOLOGICAL REVIEWS
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
- (2009) Cameron S. Brandt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response
- (2009) Kensuke Usuki et al. LEUKEMIA RESEARCH
- Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
- (2008) C. Quintarelli et al. BLOOD
- Development and dynamics of robust T-cell responses to CML under imatinib treatment
- (2008) C. I-U. Chen et al. BLOOD
- Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia
- (2008) Jochen Greiner et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
- (2008) Daniel Perez et al. INTERNATIONAL JOURNAL OF CANCER
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia
- (2007) Giulia Cervetti et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More